Drugs / DCVax-001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01127464 | May 2010 → Nov 2012 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCVax-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01127464 ↗ |
| Modality | Vaccine | “DCVax-001 is a recombinant protein vaccine designed to prevent and potentially treat human immunodeficiency virus (HIV) infection.” NCT01127464 ↗ |